Xmn1-158 γ°Variant in B-Thalassemia Intermediate Patients in South-East of Iran

Ebrahim Miri-Moghaddam†,2, Sara Bahrami3, Majid Naderi4, Ali Bazi5, Morteza Karimipoor6

1Associate Professor, Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
2Cardio Vascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
3Msc in Biology, Department of Biology, Payame Noor University, Zahedan, Iran
4Assistant Professor, Genetics of Non-Communicable Diseases Research Center, Department of Pediatric Hematology & Oncology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
5Msc in Hematology, Faculty of Allied Medical Sciences, Zabol University of Medical Sciences, Zabol, Iran
6Ph.D, Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Corresponding Author: Majid Naderi, M.D., Department of Pediatrics Hematology and Oncology, Zahedan University of Medical Sciences, Zahedan, Iran
Tel: +98-5413414567
Fax: +98-5413218998
Email: majid_naderi2000@yahoo.com

ABSTRACT

Background: Xmn-1 polymorphism of γ°globin gene (HBG2) is a prominent quantitative trait loci (QTL) in β-thalassemia intermediate (β-TI). In current study, we evaluated the frequency of Xmn-1 polymorphism and its association with β-globin gene (HBB) alleles and Hb F level in β-TI patients in Sistan and Balouchestan province, south-east of Iran.

Subjects and Methods: 45 β-TI patients were enrolled. HBB gene mutations and Xmn-1 polymorphism were determined by amplification-refractory mutation system (ARMS) PCR method. Hemoglobin profile was determined using capillary electrophoresis.

Results: The study participants consisted of 26 (58%) males and 19 (42%) females. Mean age of the patients was 10.7±3.1 years old. Overall, Xmn-1 polymorphism was observed in 28 (62%) patients. Homozygous (TT) and heterozygous (CT) genotypes of the polymorphism represented with frequencies of 12 (26%) and 16 (35%), respectively. Main recognized HBB gene mutation was IVSI-5(G>C) with homozygous frequency of 44%. Non-zero (β°) alleles of HBB gene constituted 11.1% (4 patients with heterozygous β° and one with homozygous β° genotype). Hb F level was significantly higher in patients with at least one Xmn-1 allele (67.9±17.9%) than those without the polymorphism (19.5±20.3%, P<0.0001). Also, patients with homozygous genotype demonstrated significantly higher Hb F compared to heterozygous (CT) cases (respective percentages of 85±6.8 and 54.7±10.5, p<0.0001).

Conclusion: Our results highlighted the role of Xmn-1 polymorphism as the main phenotypic modifier in β-TI patients in Sistan and Balouchestan province.

Keywords: Xmn-1 polymorphism, β-thalassemia intermediate, Hemoglobin F

INTRODUCTION

β-Thalassemia intermediate (β-TI) represents a highly heterogeneous entity lying between two extreme forms of β-thalassemia syndromes; β-thalassemia minor and β-thalassemia major. Clinical picture of β-TI ranges from non-symptomatic to severe transfusion-dependent forms. Wide-spectrum phenotypic appearance of β-TI can be partly attributed to its great genetic diversity. Accordingly, multiple genetic loci are present inside and outside of the β-globin gene (HBB) cluster which can modulate the clinical severity of β-TI. However, the main pathophysiological factor determining the severity of β-TI is the ratio of α-globin/non-α-globin chains within erythroid precursors. The majority of the known phenotype modifiers of β-TI execute through counterbalancing the above-mentioned ratio.
Multiple genetic polymorphisms within HBB like genes, specific erythroid transcription factors and genes involved in oxi-do-reductase reactions have been introduced as quantitative trait loci (QTLs) modulating β-thalassemia clinical appearance. Although the mechanisms exploited by these genetic modifiers are largely obscure, induction of Hb F is considered as an established contributor. Xmn-1 polymorphism results from a C > T base substitution at the -158 position of γ⁶ globin (HBG2) gene, and is a well-known HbF inducer ameliorating β-TI severity. This polymorphism resides in close proximity to locus control region of β-globin gene (β-LCR) which controls differential expression of β-like globin genes throughout the life. Actually, the “T” allele of Xmn-1 polymorphism leads to weaker binding of transcription inhibitors to the β-LCR, and subsequently results in persistent activation of HBG2 gene beyond the infancy period. Studies indicated substantial impact of Xmn-1 polymorphism on improvement of β-thalassemia clinical severity. Also, there are reports suggesting a role for Xmn-1 polymorphism in predicting the response rate to the Hb F inducer therapeutics in β-thalassemia major.

Nevertheless, Xmn-1 polymorphism has demonstrated a variable penetrance among different populations. In Iranian β-TI patients, this polymorphism has been characterized as the main genetic contributor to the compromised phenotype in β-thalassemia patients. Despite this, there has been no study on the frequency of this polymorphism in Sistan and Balouchestan province in south-east of Iran. Considering that the province is one of the primordial locations of β-thalassemia in the country (with estimated frequency of 2500 registered β-thalassemia major cases), we aimed to evaluate the frequency and clinical significance of Xmn-1 polymorphism in β-TI patients in this region.

MATERIALS AND METHODS

The patients (45 cases represented with β-TI) were selected from Ali-Ashgar Children Hospital, Zahedan, Sistan and Balouchestan province. These patients have been seeking medical care since their diagnosis in this center. Inclusion criteria were mild symptoms of anemia, intermittent transfusion requirements, and age of starting transfusion >2 years old. Our study was approved by the Research Deputy of Azad University, as well as the Medical Ethics Committee of the Pasteure Institute of Iran. Furthermore, an informed consent was acquired from the patients or their parents. Routine hematological indices were measured by Sysmex K1000 (Japan) blood auto analyzer. Capillary electrophoresis was performed for quantification of HbA₂ and Hb F.

DNA extraction was carried out using proteinase K method with a standard protocol previously described. Amplification-refractory mutation system (ARMS)-PCR (dNTP cat. No. DN7604C (CinnaGen Company, Karaj-Iran), TaqDNA polymerase Cat. No. TA8109C (CinnaGen Company, Karaj-Iran)) was conducted to determine the Xmn-1 polymorphism and common HBB gene mutations as previously reported in East of Iran. Furthermore, mutations identified in β-TI patients were further confirmed in patient’s parents. The sequences of the used primers (Biolegio Company, Nijmegen-Netherland) have been presented in Table 1.

Table 1: Sequences of the primers used for detection of Xmn-1 polymorphism

| Primer       | Nucleotide sequence          | Product size (bp) |
|--------------|------------------------------|-------------------|
| Forward      | 5’-CCAACCATGGGTGGATTTAGCCAAGG-3’ | 492               |
| Forward      | 5’-CCAACCATGGGTGGAGTTTAGCCAAG-3’ | 492               |
| Reverses     | 5’-CACGTAAACTGTGTCCTTATAGGATTT-3’ | 492               |

RESULTS

The current study included 45 unrelated patients diagnosed with β-TI. Mean age of the patients was 10.7±3.1 years old. Detailed demographic and clinical features have been represented in Table 2. The most identified β-globin gene mutations were IVSI-5 (G>C), IVSI-II (G>A) and -88(C>T) with frequencies of 60%, 10% and 6.5%, respectively. Homozygous state for IVSI-5 (G>C) (44%) was the most frequent genotypic combination. Other common genotypes comprised IVSI-5 (G>C)/-88(C>T) with 8.9%, IVSI-5 (G>C)/IVSI-II (G>A), homozygous IVSI-II (G>A) and IVSI-5 (G>C)/HbS, each with 6.7% prevalence (Table 3).
Table 2: Demographic and clinical features in 45 unrelated β-TI patients

| Parameters      | Male (n=26) |          | Female (n=19) |          |
|-----------------|-------------|----------|--------------|----------|
| Hb (g/dl)       |             |          |              |          |
| <7              | 7           | 26.9     | 3            | 15.7     |
| 7-10            | 16          | 61.5     | 16           | 84.2     |
| >10             | 3           | 11.5     | 0            | 0        |
| MCV (fL)        |             |          |              |          |
| <80             | 25          | 96.1     | 16           | 84.2     |
| >80             | 1           | 3.8      | 3            | 15.7     |
| MCH (Pg)        |             |          |              |          |
| <27             | 23          | 88.4     | 18           | 94.7     |
| >27             | 3           | 11.5     | 1            | 5.2      |
| RBC(10¹²/L)     |             |          |              |          |
| <4.2            | 16          | 61.5     | 12           | 63.1     |
| >4.2            | 10          | 38.4     | 7            | 36.8     |
| Hb A₂ (%)       |             |          |              |          |
| <2.5            | 7           | 26.9     | 4            | 21       |
| 2.5-3.5         | 5           | 19.2     | 5            | 26.3     |
| >3.5            | 14          | 53.8     | 10           | 52.6     |
| Hb F (%)        |             |          |              |          |
| <5              | 0           | 0        | 5            | 26.3     |
| 5-50            | 9           | 34.6     | 6            | 31.5     |
| >50             | 17          | 65.3     | 8            | 42.1     |
| Splenectomy     |             |          |              |          |
| Yes             | 1           | 3.8      | 0            | 0        |
| No              | 25          | 96.1     | 19           | 100      |
| Age of Diagnosis (years)* |         |          |              |          |
| Less than 5     | 13          | 65       | 12           | 70       |
| Above 5         | 7           | 35       | 5            | 30       |

* Data was not available for 8 patients.

Table 3: Mutations of β-globin gene were identified in 45 unrelated β-TI patients.

| N   | Genotype                      | Type     | N | % | Xmn-1 polymorphism | Mean Hb F % (SD) |
|-----|-------------------------------|----------|---|---|-------------------|-----------------|
|     |                               |          |   |   | CC    | CT   | TT   |               |               |
| 1   | IVSI-S/IVSI-S                 | β°/β°   | 20 | 44.4 | 12  | 4   | 4   | 45.4(35.9)   |               |
| 2   | IVSI-S/IVSI-I                 | β°/β°   | 3  | 6.7  | 0   | 2   | 1   | 60.7(33.9)   |               |
| 3   | IVSI-S/-88(C>T)               | β°/β°   | 4  | 8.9  | 1   | 3   | 0   | 47.5(19.3)   |               |
| 4   | IVSI-S/Normal                 | β°/βº  | 2  | 4.4  | 0   | 2   | 0   | 62.5(49.4)   |               |
| 5   | IVSI-S/Hbs                    | β°/β°   | 3  | 6.7  | 1   | 2   | 0   | 40.1(33.1)   |               |
| 6   | IVSI-S/FSC 8/9                | β°/β°   | 1  | 2.2  | 0   | 1   | 0   |               |               |
| 7   | IVSI-S/Del619                 | β°/βº  | 1  | 2.2  | 1   | 0   | 0   |               |               |
| 8   | IVSI-1/IVSI-I                 | β°/β°   | 3  | 6.7  | 0   | 0   | 3   | 91(6.6)      |               |
| 9   | IVSI(-25Del)/Normal           | β°/βº  | 2  | 4.4  | 0   | 1   | 1   | 57.2(30.7)   |               |
| 10  | FSC8/9-FSC8/9                 | β°/β°   | 2  | 4.4  | 0   | 1   | 1   | 74.3(23)     |               |
| 11  | Codo15/Codo15                 | β°/β°   | 1  | 2.2  | 1   | 0   | 0   |               |               |
| 12  | -88(C>T)/-88(C>T)             | β°/β°   | 1  | 2.2  | 0   | 0   | 1   |               |               |
| 13  | Unk/Unk                       | -       | 2  | 4.4  | 1   | 0   | 1   | 41.6(30.1)   |               |
| Total|                              |          | 45 | 100.0 | 17  | 16  | 12 |               |               |

Xmn-1 polymorphism was observed in 28/45 (62.2%) of our patients (Figure 1). In 12 (26%) out of 45, a homozygous genotype (TT) was observed, while 16/45 (35%) had heterozygous (CT) status. Mean Hb F was significantly higher (67.9±17.9 %) in the β-TI patients who had at least one Xmn-1 polymorphism in comparison with the patients who represented without the polymorphism (19.5±29.3, P=0.0001). Furthermore, cases with homozygous genotype of Xmn-1 polymorphism had significantly higher mean Hb F percentage (85.5%) than the heterozygous cases (54.7%, P=0.0001, Table 4).
DISCUSSION

Xmn-1 polymorphism is a prominent mediator ameliorating β-thalassemia phenotype through inducing fetal hemoglobin expression. This polymorphism exhibited 62.3% frequency in the present study with 35.6% heterozygous and 26.7% homozygous genotypes. In a recent study on 51 Iranian β-TI patients, 68.6% of whom showed CT genotype of Xmn-1 polymorphism, while TT genotype was identified in none of the cases. In other studies in Iran, Arab et al. and Akbariet reported the respective Xmn-1 frequencies of 76.9% and 60% in β-TI patients. In the study of Karimi et al. in our neighbor province, Fars, Xmn-1 variant was detected in 40.6% of 48 β-TI patients and 14% of 50 healthy subjects. In another study in the western province, Kermanshah, 16.3% and 22.3% of patients with severe form of β-thalassemia demonstrated homozygous and heterozygous genotypes of Xmn-1 variant. In studies conducted in Iraq and Kuwait, Xmn-1 polymorphism was described in 47% and 75% of β-TI patients, respectively. We observed that Hb F level was significantly higher in patients who had at least one Xmn-1 variant allele than the patients without this polymorphism (67% vs. 19%). This is in consistent with results obtained by Motovali et al. and Galanello et al. In addition, we found that the patients who were homozygous for Xmn-1 polymorphism had significantly higher mean Hb F (85.5%) compared to heterozygous subjects (54.7%), which is consistent with the findings from prior works.

In parallel, Nemati et al. also reported a higher level of HbF in β-thalassemia patients with homozygous genotype of Xmn-1 polymorphism than the ones without this genetic combination. From molecular perspective, “T” base substitution at Xmn-1 polymorphic site is supposed to interfere with interaction of specific transcription inhibitors with regulatory sequences at β-LCR. This may be suggestive for possible effects of Xmn-1 polymorphism in bypassing the attachment of the specific transcriptional inhibitors to the regulatory sequences of HBG2 gene. This idea is further supported by studies indicating that polymorphisms in two main suppressive mediators of HBG2 expression, BCL11A and MYB are associated with moderate clinical picture in β-thalassemia major. These findings conclusively indicate that main QTLs of β-thalassemia phenotype, including Xmn-1 polymorphism potentially interfere with binding of inhibitory transcription factors responsible for silencing of Hb F expression. This is particularly important for consideration of targeted therapies interfering with interaction of these transcription inhibitors with β-LCR.

Collocation of Xmn-1 polymorphism with specific β-thalassemia alleles have been suggested in β-TI patients. In this regard, a significant association has been described between homozygous state of IVS-II-I (G>A) mutation and Xmn-1 polymorphism by Karimi et al. In line with this finding, we also detected the presence of Xmn-1 polymorphism in all six patients who had at least one IVS-II-I (G>A) allele (Table 2). Along with this, from 20 patients with homozygous IVS-I-5(G>C) genotype, 8 (40%) had at least one Xmn-1 allele which may be in part indicative of a relationship between this allele and co inheritance of Xmn-1 polymorphism. Furthermore, Xmn-1 polymorphism was observed in both patients homozygous for FSC8/9 (+G) allele. Nevertheless, the number of our patients with...
either IVS-II-1 (G>A), IVSI-5(G>C) or FSC8/9(+G) mutation was not adequate for exploiting a certain association. Larger population-based studies are recommended to confirm a potential link between certain HBB alleles and Xmn-1 polymorphism.

It has been suggested that Xmn-1 polymorphism may be restricted to specific β-TI genotypic combinations. Reportedly, the main genetic signature harboring Xmn-1 polymorphism in β-TI patients has been inherited β₀ alleles. In parallel, we identified the Xmn-1 polymorphism in 17/31 (54%) and 3/4 (75%) of our patient who had β₀/β₀ and β₀/β₁ signatures, respectively. In accordance with our results, Xmn-1 polymorphism has also been associated with β₀ thalassemia mutations in 55%-60% of intermediate patients in earlier reports from Iran. Likewise, association of Xmn-1 polymorphism with β₀ mutations reached as high as 80 % in an Iraqi study. This association was also proposed in the study of Adekile et al., in which Xmn-1 polymorphism co-inherited with β₀ alleles was more frequent than β₁ alleles in β-TI patients. To sum up, the proposed relationship between inheritance of β₀ alleles and Xmn-1 polymorphism highlights the role of this polymorphism as a strong modifying factor in severe β₀-thalassemia cases.

There are some reports that are not in accordance with the defined role of Xmn-1 polymorphism in lessening the clinical presentation or boosting Hb F level in β-thalassemia patients. This notion can be understood from the identification of some patients harboring Xmn-1 polymorphism, and phenotypic picture of β-thalassemia major. These observations may highlight the impact of some unidentified genetic determinants acting upstream of Xmn-1 polymorphism. On the other hand, neither Xmn-1 polymorphism nor mild β-globin mutations were detected in 13 (27%) of our patients, indicating the possible contribution of other QTLs such as polymorphisms in BCLA11 and HBS1L-MYB transcription factors. More studies on the molecular aspects of β-TI patients can provide us with a wider view on genetic contributors to the phenotype of β-thalassemia syndromes. Besides, there may be also a possible role for participation of other unrecognized factors acting independent of Hb F induction to alleviate the β-thalassemia phenotype. Since therapeutic strategies aiming to induction of Hb F have largely yielded inconsistent results in β-thalassemia syndromes, identification of Hb F independent mechanisms provides a new promising field of research in this area.

CONCLUSION

Our results revealed the Xmn-1 polymorphism as the most prominent molecular basis of β-TI in Sistan and Balouchestan province. However, further studies are recommended for elucidating the possible role of other known QTLs to the better understanding of β-TI molecular basis in our region.

ACKNOWLEDGEMENT

Special thanks to the patients and their families for their kind contribution to the study.

CONFLICT OF INTEREST:

Authors declare that they have no conflict of interests.

REFERENCES

1. Neishabury M, Azarkeivan A, Oberkanins C, et al. Molecular mechanisms underlying thalassemia intermedia in Iran. Genetic testing. 2008;12(4):549-56. 2. Galanello R, Origa R. Review: beta-thalassemia. Orphanet J Rare Dis. 2010;5(1):11. 3. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;Suppl 1:S3-6. doi: 10.1016/S0268-690X(12)70003-6. 4. Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemia. Blood Rev. 2012;26;(Suppl 1):s7–s11. 5. Mohammadi-Asl J, Ramezani A, Norozi F, et al. The Influence of Polymorphisms in Disease Severity in β-Thalassemia. Biochem Genet. 2015:53(9-10):235-43. 6. Bank A. Regulation of human fetal hemoglobin: new players, new complexities. Blood. 2006;107(2):435-43. 7. Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12(2):61-76. 8. Motovali-Bashi M, Ghasemi T. Role of XmnI Polymorphism in Hydroxyurea Treatment and Fetal Hemoglobin Level at Isfahani Intermediate β-Thalassemia Patients. Iran Biomed J. 2015;19(3):177-182. 9. Bhagat S, Patra PK, Thakur AS. Association between Xmnl Polymorphism and HbF Level in Sickle Cell Disease
Patients from Chhattisgarh. Int J Biomed Sci. 2012;8(1):36-9.
10. Khelil AH, Morinière M, Laradi S, Khelif A, Perrin P, Chibani JB, et al. Xmn I polymorphism associated with concomitant activation of G γ and A γ globin gene transcription on a β 0-thalassemia chromosome. Blood Cells Mol Dis. 2011;46(2):133-8.
11. Hanif TB, Ahmed S, Anwar J, et al. XmnI polymorphism and disease severity in patients with beta-thalassemia from northern Pakistan. J Ayub Med Coll Abbottabad. 2015;27(1):13-6.
12. Verma IC, Kleanthous M, Saxena R, et al. Multicenter study of the molecular basis of thalassemia intermedia in different ethnic populations. Hemoglobin. 2007;31(4):439-52.
13. Ansari SH, Shamsi TS, Munzir S, et al. Ggamma-Xmn I polymorphism: a significant determinant of beta-thalassemia treatment without blood transfusion. J Pediatr Hematol Oncol. 2013;35(4):e153-6.
14. Alebouyeh M, Moussavi F, Haddad-Deylami H, et al. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann Hematol. 2004;83(7):430-3.
15. Karimi M, Yarmohammadi H, Farjadian S, et al. β-Thalassemia intermedia from southern Iran: IVS-II-1 (G→A) is the prevalent thalassemia intermedia allele. Hemoglobin. 2002;26(2):147-54.
16. Qatanani M, Taher A, Koussa S, et al. β-Thalassemia intermedia in Lebanon. Eur J Haematol. 2000;64(4):237-44.
17. Arab A, Karimipoor M, Rajabi A, et al. Molecular characterization of β-thalassemia intermedia: a report from Iran. Mol Biol Rep. 2011;38(7):4321-6.
18. Akbari MT, Izadi P, Izadyar M, et al. Molecular basis of thalassemia intermedia in Iran. Hemoglobin. 2008;32(5):462-70.
19. Eshghi P, Zadeh-Vakili A, Rashidi A, et al. An unusually frequent β-thalassemia mutation in an Iranian province. Hemoglobin. 2008;32(4):387-92.
20. Miri-Moghaddam E, Zadeh-Vakili A, Nikravesh A, et al. Sistani population: a different spectrum of β-thalassemia mutations from other ethnic groups of Iran. Hemoglobin. 2013;37(2):138-47.
21. Miri-Moghaddam E, Naderi M, Izadi S, et al. Causes of new cases of major thalassemia in sistan and balouchistan province in South-East of iran. Iranian journal of public health. 2012;41(11):67.
22. Ahmad NN, Cu-Unjieng AB, Donoso LA. Modification of standard protease K/ phenol method for DNA isolation to improve yield and purity from frozen blood. J Med Genet. 1995;32(2):129-30.
23. Miri-Moghaddam E, Zadeh-Vakili A. Profile of β-Thalassemia and its Prenatal Diagnosis in Khorasan-E-Jonobi Province, Iran. Hemoglobin. 2012;36(5):456-63.
24. Miri-Moghaddam E, Zadeh-Vakili A, Rouhani Z, et al. Molecular basis and prenatal diagnosis of β-thalassemia among Balouch population in Iran. Prenat Diagn. 2011;31(8):788-91.
25. Taher AT, Musallam KM, Cappellini MD. Thalassaemia intermedia: an update. Mediterr J Hematol Infect Dis. 2009;1(1):e2009004.doi: 10.4084/MJHID.2009.004.
26. Their SL, Menzel S, Lathrop M, et al. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet. 2009;18(R2):R216-R23.
27. Nemati H, Rahimi Z, Bahrami G. The Xmn1 polymorphic site 5' to the Gγ gene and its correlation to the Gγ: Aγ ratio, age at first blood transfusion and clinical features in β-Thalassemia patients from Western Iran. Mol Biol Rep. 2010;37(1):159-64.
28. Shamoony RP, Al-Allawi NA, Cappellini MD, et al. Molecular basis of beta-thalassemia intermedia in Erbil province of Iraqi Kurdistan. Hemoglobin. 2015;39(3):178-83.
29. Adekile AD, Azab AF, Al-Sharida SI, et al. Clinical and molecular characteristics of non-transfusion-dependent thalassemia in Kuwait. Hemoglobin. 2015;39(5):320-6.
30. Galanello R, Sanna S, Persei L, et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood. 2009;114(18):3935-7.
31. Kumar R, Kaur A, Agarwal S. Influence of Xmn1 1(G)gamma (HBG2 c.-211 C --> T) Globin Gene Polymorphism on Phenotype of Thalassemia Patients of North India. Indian J Hematol Blood Transfus. 2014;30(4):286-90.
32. Dadheech S, Jain S, Madhulatha D, et al. Association of Xmn1 -158 gammaG variant with severity and HbF levels in beta-thalassemia major and sickle cell anaemia. Mol Biol Rep. 2014;41(5):3331-7.
33. Their SL. Genetic association studies in β-hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2013;2013:354-61.
34. Sedgewick AE, Timofeev N, Sebastiani P, et al. BCL11A is a major HbF quantitative trait locus in three different populations with β-hemoglobinopathies. Blood Cells Mol Dis. 2008;41(3):255-8.
35. Fanis P, Koussiappa I, Phylactides M, et al. Genotyping of BCL11A and HBS1L-MYB SNPs associated with fetal hemoglobin levels: a SNaPshot minisequencing approach. BMC Genomics. 2014;15(1):108.
36. Gorji F, Hamid M, Arab A, et al. Relationship between DNA polymorphisms at the BCL11A and HBS1L-MYB loci in β-Thalassemia patients with increased fetal
hemoglobin levels. Sci J Blood Transfus Organ. 2011;8(3):149-57.
37. Neishabury M, Azarkeivan A, Najmabadi H. Frequency of Positive Xmn1 G γ polymorphism and coinheritance of common alpha thalassemia mutations do not show statistically significant difference between thalassemia major and intermedia cases with homozygous IVSII-1 mutation. Blood Cells Mol Dis. 2010;44(2):95-9.
38. Oberoi S, Das R, Panigrahi I, et al. Xmn1-G gamma polymorphism and clinical predictors of severity of disease in β-thalassemia intermedia. Pediatr Blood Cancer. 2011;57(6):1025-8.
39. Oberoi S, Das R, Panigrahi I, et al. Xmn1-G gamma polymorphism and clinical predictors of severity of disease in beta-thalassemia intermedia. Pediatr Blood Cancer. 2011;57(6):1025-8.
40. Hamid M, Mahjoubi F, Akbari MT, et al. Molecular analysis of γ-globin promoters, HS-111 and 3’ HS1, in β-thalassemia intermedia patients associated with high levels of Hb F. Hemoglobin. 2009;33(6):428-38.
41. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci U S A. 2008;105(5):1620-5.